{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:40:33Z","timestamp":1785886833225,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:00:00Z","timestamp":1583539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:00:00Z","timestamp":1583539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10620-020-06181-x","type":"journal-article","created":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T03:02:31Z","timestamp":1583550151000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?"],"prefix":"10.1007","volume":"66","author":[{"given":"Claire L.","family":"Jansson-Knodell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Enzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinash","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,7]]},"reference":[{"key":"6181_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"6181_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"key":"6181_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.cgh.2019.02.043","volume":"17","author":"R Panaccione","year":"2019","unstructured":"Panaccione R, Steinhart AH, Bressler B, et al. Canadian association of gastroenterology clinical practice guideline for the management of luminal Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2019;17:1680\u20131713.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6181_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/apt.12749","volume":"39","author":"RW Stidham","year":"2014","unstructured":"Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39:1349\u20131362.","journal-title":"Aliment Pharmacol Ther"},{"key":"6181_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/apt.12644","volume":"39","author":"RW Stidham","year":"2014","unstructured":"Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660\u2013671.","journal-title":"Aliment Pharmacol Ther"},{"key":"6181_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/MIB.0000000000001199","volume":"23","author":"HM Cohn","year":"2017","unstructured":"Cohn HM, Dave M, Loftus EV Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1301\u20131315.","journal-title":"Inflamm Bowel Dis"},{"key":"6181_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.gtc.2009.07.005","volume":"38","author":"W Afif","year":"2009","unstructured":"Afif W, Loftus EV Jr. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin N Am. 2009;38:691\u2013709.","journal-title":"Gastroenterol Clin N Am"},{"key":"6181_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","volume":"10","author":"K Lis","year":"2014","unstructured":"Lis K, Kuzawinska O, Balkowiec-Iskra E. Tumor necrosis factor inhibitors\u2014state of knowledge. Arch Med Sci. 2014;10:1175\u20131185.","journal-title":"Arch Med Sci"},{"key":"6181_CR9","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.cgh.2016.07.019","volume":"14","author":"EV Loftus Jr","year":"2016","unstructured":"Loftus EV Jr, Colombel JF, Schreiber S, et al. Safety of long-term treatment with certolizumab pegol in patients with Crohn\u2019s disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol. 2016;14:1753\u20131762.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6181_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/MIB.0b013e3182a827d2","volume":"20","author":"M Dave","year":"2014","unstructured":"Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196\u2013212.","journal-title":"Inflamm Bowel Dis"},{"key":"6181_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","volume":"45","author":"LJ Wheat","year":"2007","unstructured":"Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin Infect Dis. 2007;45:807\u2013825.","journal-title":"Clin Infect Dis"},{"key":"6181_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3201\/eid2403.171258","volume":"24","author":"PA Armstrong","year":"2018","unstructured":"Armstrong PA, Jackson BR, Haselow D, et al. Multistate epidemiology of histoplasmosis, United States, 2011\u20132014. Emerg Infect Dis. 2018;24:425\u2013431.","journal-title":"Emerg Infect Dis"},{"key":"6181_CR13","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.160.12.6072","volume":"160","author":"R Allendoerfer","year":"1998","unstructured":"Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol. 1998;160:6072\u20136082.","journal-title":"J Immunol"},{"key":"6181_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","volume":"36","author":"DE Furst","year":"2006","unstructured":"Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159\u2013167.","journal-title":"Semin Arthritis Rheum"},{"key":"6181_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"KL Wood","year":"2003","unstructured":"Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167:1279\u20131282.","journal-title":"Am J Respir Crit Care Med"},{"key":"6181_CR16","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"JH Lee","year":"2002","unstructured":"Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565\u20132570.","journal-title":"Arthritis Rheum"},{"key":"6181_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/cid\/cir435","volume":"53","author":"CA Hage","year":"2011","unstructured":"Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53:448\u2013454.","journal-title":"Clin Infect Dis"},{"key":"6181_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-2334-11-145","volume":"11","author":"TC Olson","year":"2011","unstructured":"Olson TC, Bongartz T, Crowson CS, Roberts GD, Orenstein R, Matteson EL. Histoplasmosis infection in patients with rheumatoid arthritis, 1998\u20132009. BMC Infect Dis. 2011;11:145.","journal-title":"BMC Infect Dis"},{"key":"6181_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ibd.21378","volume":"17","author":"JL Dotson","year":"2011","unstructured":"Dotson JL, Crandall W, Mousa H, et al. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17:56\u201361.","journal-title":"Inflamm Bowel Dis"},{"key":"6181_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","volume":"83","author":"S Tsiodras","year":"2008","unstructured":"Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181\u2013194.","journal-title":"Mayo Clin Proc"},{"key":"6181_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1086\/648724","volume":"50","author":"CA Hage","year":"2010","unstructured":"Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50:85\u201392.","journal-title":"Clin Infect Dis"},{"key":"6181_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261\u20131265.","journal-title":"Clin Infect Dis"},{"key":"6181_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ299","volume":"61","author":"P Vergidis","year":"2015","unstructured":"Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015;61:409\u2013417.","journal-title":"Clin Infect Dis"},{"key":"6181_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u2013381.","journal-title":"J Biomed Inform"},{"key":"6181_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/MIB.0000000000000002","volume":"20","author":"JM Swoger","year":"2014","unstructured":"Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis.. 2014;20:926\u2013935.","journal-title":"Inflamm Bowel Dis."},{"key":"6181_CR26","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1093\/ibd\/izy372","volume":"25","author":"BS Pabla","year":"2019","unstructured":"Pabla BS, Scoville EA, Sarker S, et al. Histoplasmosis as a complication of inflammatory bowel disease therapy: a case series. Inflamm Bowel Dis. 2019;25:e69\u2013e70.","journal-title":"Inflamm Bowel Dis"},{"key":"6181_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1086\/313752","volume":"30","author":"J Wheat","year":"2000","unstructured":"Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Infectious diseases society of America. Clin Infect Dis. 2000;30:688\u2013695.","journal-title":"Clin Infect Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06181-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06181-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:12:36Z","timestamp":1695888756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06181-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["6181"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06181-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,7]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Abinash Virk: inventor for travel health and wellness, LLC. Edward V Loftus Jr.: consulting for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Takeda, UCB; and research support from AbbVie, Amgen, Celgene\/Receptos, Genentech, Gilead, Janssen, Medimmune, Pfizer, Robarts Clinical Trials, Takeda, UCB. Other authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Mayo Clinic Institutional Review Board (IRB 18-002325). Patients who declined authorization for review of medical records for research purposes were excluded. For this type of study, formal consent was not required due to its retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}